Want to see HK:9886 full AI Analyst Report?
9886 Stock Chart & Stats
HK$1.08
-HK$0.02(-3.23%)
At close: 4:00 PM EST
HK$1.08
-HK$0.02(-3.23%)
Day’s Range― - ―
52-Week RangeHK$0.50 - HK$1.37
Previous CloseN/A
Volume431.00K
Average Volume (3M)4.91M
Market Cap
HK$1.20B
Enterprise ValueHK$845.29M
Total Cash (Recent Filing)HK$1.12B
Total Debt (Recent Filing)HK$281.81M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,254,649,400
10 Day Avg. Volume8,114,443
30 Day Avg. Volume4,906,414
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)0.75
Price to Sales (P/S)0.26
P/FCF Ratio10.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.07
Revenue Forecast (FY)HK$6.85B
Bulls Say, Bears Say
Bulls Say
Revenue ReboundSharp revenue rebound in 2025 provides durable top-line momentum after prior declines. Higher sales increase scale, improve fixed-cost absorption and unit economics, and create room to reinvest in the O2O pharmacy network and logistics, supporting sustainable operating leverage.
Improving MarginsMargin expansion to roughly 35% and materially narrower losses reflect improving unit economics and cost control. Sustained higher gross margins bolster the path to operating profitability, reduce cash burn per sale, and increase resilience of the business model over the medium term.
Positive Cash GenerationConversion to positive operating and free cash flow materially improves financial flexibility. Reliable cash generation lowers dependence on external financing, enables reinvestment in tech, fulfillment and stores, and supports durable scaling of the O2O pharmacy and delivery ecosystem.
Bears Say
Remaining UnprofitableDespite progress, the company is still slightly unprofitable in 2025 which limits retained earnings and internal funding capacity. Persistent near-term losses prolong execution risk and mean the business must sustain improvement to deliver durable, self-funded growth and positive investor returns.
Cash-flow VolatilityHistoric multi-year negative cash flows indicate volatility; the 2025 cash turnaround may reflect working-capital or timing effects. This irregularity reduces predictability of funding for operations and expansion and raises the risk that positive cash flow is not yet fully durable.
Legacy Balance-sheet StressA history of negative equity and high leverage in 2020–2021 and negative ROE through 2025 points to capital inefficiency and prior distress. Even with current manageable debt ratios, legacy balance-sheet issues increase vulnerability to shocks and could necessitate future capital or repricing.
Dingdang Health Technology Group Ltd. News
9886 FAQ
What was Dingdang Health Technology Group Ltd.’s price range in the past 12 months?
Dingdang Health Technology Group Ltd. lowest stock price was HK$0.49 and its highest was HK$1.37 in the past 12 months.
What is Dingdang Health Technology Group Ltd.’s market cap?
Dingdang Health Technology Group Ltd.’s market cap is HK$1.20B.
When is Dingdang Health Technology Group Ltd.’s upcoming earnings report date?
Dingdang Health Technology Group Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 47 days.
How were Dingdang Health Technology Group Ltd.’s earnings last quarter?
Dingdang Health Technology Group Ltd. released its earnings results on Mar 20, 2026. The company reported HK$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.002.
Is Dingdang Health Technology Group Ltd. overvalued?
According to Wall Street analysts Dingdang Health Technology Group Ltd.’s price is currently Overvalued.
Does Dingdang Health Technology Group Ltd. pay dividends?
Dingdang Health Technology Group Ltd. does not currently pay dividends.
What is Dingdang Health Technology Group Ltd.’s EPS estimate?
Dingdang Health Technology Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dingdang Health Technology Group Ltd. have?
Dingdang Health Technology Group Ltd. has 1,254,649,400 shares outstanding.
What happened to Dingdang Health Technology Group Ltd.’s price movement after its last earnings report?
Dingdang Health Technology Group Ltd. reported an EPS of HK$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.205%.
Which hedge fund is a major shareholder of Dingdang Health Technology Group Ltd.?
Currently, no hedge funds are holding shares in HK:9886
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dingdang Health Technology Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.00%
12-Months-Change
Fundamentals
Return on Equity
-2.95%
Trailing 12-Months
Asset Growth
12.67%
Trailing 12-Months
Company Description
Dingdang Health Technology Group Ltd.
Dingdang Health Technology Group Ltd. is a digital retail pharmacy firm operating within the People's Republic of China. The company provides online sales of pharmaceutical products alongside medical consultation services. Founded in 2014, it is based in Beijing, China.
Technical Analysis
Innovative Pharmaceutical Biotech
―
Natural Beauty Bio-Technology
―
Cheerwin Group Limited
―
EC Healthcare
―
Giant Biogene Holding Co. Ltd.
―
Options Prices
Currently, No data available
---